# Orna Therapeutics

Orna Therapeutics is an Asset Manager based in Cambridge, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Cambridge, United States
- **Region:** North America
- **Address:** Cambridge, MA, United States
- **Assets under management:** Undisclosed
- **Website:** ornatx.com
- **LinkedIn:** https://www.linkedin.com/company/ornatx

## Regulatory record

- **Reports private funds:** No

## About

Orna Therapeutics is leaving linear thinking behind to create fully engineered circular RNA (oRNA) therapeutics – an entirely new class of RNA medicines.

## Sectors

- Biotechnology
- Digital Health
- Healthcare Services

## People

- Joe — Chief Scientific Officer
- Hope — General Counsel
- Ciaran — Chief Operating Officer
- Teresa Lipcsey — Chief Financial Officer
- Frank Neumann — Chief Medical Officer
- Siva — Chief Technology Officer
- Brian — Chief Business Officer

## Questions

### Who runs investment decisions at Orna Therapeutics?

Orna Therapeutics is an operating biotech company, not an investment firm. Business and R&D decisions are made by the executive team led by CSO Joe, COO Ciaran, CBO Brian, CTO Siva, and CMO Frank Neumann, with oversight from its venture backers including MPM BioImpact.

### What distinguishes Orna’s circular RNA from linear mRNA?

Orna’s engineered circular RNA is more stable than linear mRNA and, when paired with the firm’s proprietary lipid nanoparticles, can reach tissues beyond the liver. This capability opens therapeutic windows in oncology, autoimmune disease, and genetic disorders that current linear-mRNA approaches cannot readily address.

### Which diseases does Orna’s pipeline target?

The internal pipeline uses panCAR in vivo CAR technology for oncology and autoimmune diseases. A collaboration with Merck targets infectious-disease applications. The delivery platform also shows potential for genetic diseases such as sickle-cell disease and beta-thalassemia by delivering directly to bone marrow without harsh preconditioning regimens.

### Does Orna Therapeutics participate in external partnerships?

Yes. Its most prominent partnership is with Merck, focused on developing oRNA-based vaccines and therapeutics for infectious diseases. The firm has not disclosed additional active external collaborations but continues to evaluate strategic business-development opportunities per the 2024 appointment of its Chief Business Officer.

### Where is Orna’s manufacturing and delivery expertise coming from?

CTO Siva previously led manufacturing at Alnylam and contributed to the launch of Onpattro, Givlaari, and Oxlumo. The team also includes former Moderna delivery and operations leaders who helped build early internal capabilities in LNP formulation and scalable mRNA manufacturing.

## Related profiles

- [Alaris Equity Partners](https://altss.com/profile/alaris-equity-partners)
- [Garaga](https://altss.com/profile/garaga-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/orna-therapeutics

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology